Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) is 4.04% higher on its value in year-to-date trading and has touched a low of $17.05 and a high of $36.72 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ARWR stock was last observed hovering at around $19.02 in the last trading session, with the day’s gains setting it 0.54%.
Currently trading at $19.56, the stock is 1.37% and -6.08% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.93 million and changing 2.84% at the moment leaves the stock -14.68% off its SMA200. ARWR registered -42.57% loss for a year compared to 6-month loss of -29.23%. The firm has a 50-day simple moving average (SMA 50) of $20.8268 and a 200-day simple moving average (SMA200) of $22.925375.
The stock witnessed a -12.56% gain in the last 1 month and extending the period to 3 months gives it a -7.30%, and is 5.79% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.99% over the week and 5.48% over the month.
Arrowhead Pharmaceuticals Inc (ARWR) has around 609 employees, a market worth around $2.43B and $3.55M in sales. Profit margin for the company is -16882.37%. Distance from 52-week low is 14.72% and -46.73% from its 52-week high. The company has generated returns on investments over the last 12 months (-58.15%).
with sales reaching $19.05M over the same period.The EPS is expected to grow by 49.64% this year, but quarterly earnings will post 7,665.61% year-over-year. Quarterly sales are estimated to grow 436.47% in year-over-year returns.
Arrowhead Pharmaceuticals Inc (ARWR) Top Institutional Holders
373.0 institutions hold shares in Arrowhead Pharmaceuticals Inc (ARWR), with institutional investors hold 83.43% of the company’s shares. The shares outstanding are 124.38M, and float is at 115.84M with Short Float at 8.64%. Institutions hold 79.71% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 15.68 million shares valued at $407.61 million. The investor’s holdings represent 12.7211% of the ARWR Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 12.21 million shares valued at $317.44 million to account for 9.9072 of the shares outstanding. The other top investors are AVORO CAPITAL ADVISORS LLC which holds 8.89 million shares representing 7.21% and valued at over $231.02 million, while FMR LLC holds 5.5256 of the shares totaling 6.81 million with a market value of $177.05 million.
Arrowhead Pharmaceuticals Inc (ARWR) Insider Activity
The most recent transaction is an insider sale by Hamilton James C, the company’s Chief Discovery/Trans Medicine. SEC filings show that Hamilton James C sold 32,729 shares of the company’s common stock on Jan 06 ’25 at a price of $19.82 per share for a total of $0.65 million. Following the sale, the insider now owns 0.27 million shares.
Arrowhead Pharmaceuticals Inc disclosed in a document filed with the SEC on Jan 06 ’25 that O’Brien Patrick (COO and General Counsel) sold a total of 29,184 shares of the company’s common stock. The trade occurred on Jan 06 ’25 and was made at $19.82 per share for $0.58 million. Following the transaction, the insider now directly holds 0.54 million shares of the ARWR stock.
Still, SEC filings show that on Jan 07 ’25, O’Brien Patrick (COO and General Counsel) disposed off 8,000 shares at an average price of $19.69 for $0.16 million. The insider now directly holds 527,201 shares of Arrowhead Pharmaceuticals Inc (ARWR).
